Dasatinib, Temsirolimus, and Cyclophosphamide in Treating Patients With Advanced, Recurrent, or Refractory Solid Tumors
Status:
Recruiting
Trial end date:
2021-10-31
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of dasatinib and temsirolimus when
given together with cyclophosphamide in treating patients with solid tumors that have spread
to other places in the body, have come back, or have not respond to previous treatment.
Dasatinib and temsirolimus may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth. Drugs used in chemotherapy, such as cyclophosphamide, work in
different ways to stop the growth of tumor cells, either by killing the cells, by stopping
them from dividing, or by stopping them from spreading. Giving dasatinib and temsirolimus
together with cyclophosphamide may be a better treatment for advanced solid tumors.